Analyst Consensus ?
ConsensusBuy49 ratings
Bullish3367.3%
Neutral1632.7%
Bearish00.0%
Edwards Lifesciences Corporation · EW · FY2026 Q2 · Calendar Q3 2026
Edwards Lifesciences Beats on Q2, Raises Full-Year Sales Guidance
Edwards Lifesciences delivered a strong Q2 2026 with 12.5% YoY sales growth to $1.74 billion, beating EPS estimates by 5.0% and revenue estimates by 2.4%. The quarter was driven by broad adoption across TAVR, TMTT, and Surgical portfolios, with a competitor exit contributing to TAVR market share gains. Management raised full-year sales guidance from 8-10% to 10-11%, and the stock recovered 3.8% over subsequent sessions after an initial 1.5% dip, suggesting the market viewed the raise as well-supported despite tax and FX headwinds.
Reported After market closeNYSEHealthcare
$48.18B market cap
100quality score
Company context
Snapshot as of publicationEdwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems.…
Earnings scorecard
Reported versus consensus
Reported EPS
$0.78
Consensus $1
EPS surprise
+5.0%
Reported versus consensus
Reported revenue
$1.74B
Consensus $1.70B
Revenue surprise
+2.4%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$85.76Current
$70Low
$100.08Average
$140High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Jul 24, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Truist Securities | Hold | Hold | Maintain | Jul 16, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| BTIG | Buy | Buy | Maintain | Jun 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 2, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 27, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Apr 24, 2026 |
| Baird | Neutral | Neutral | Maintain | Apr 24, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 11, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 11, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 20, 2026 |
| UBS | Neutral | Neutral | Maintain | Jan 12, 2026 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Oct 29, 2025 |
| Jefferies | Buy | Hold | Upgrade | Oct 29, 2025 |
| Oppenheimer | Perform | Outperform | Downgrade | Oct 8, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 25, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 15, 2025 |
| B of A Securities | Buy | Neutral | Upgrade | Dec 16, 2024 |
| OTR Global | Positive | Mixed | Upgrade | Mar 26, 2024 |
| Raymond James | Market Perform | Outperform | Downgrade | Feb 6, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 27, 2022 |
| Bernstein | Outperform | Market Perform | Upgrade | Mar 16, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Jan 7, 2022 |
| Atlantic Equities | Neutral | Neutral | Maintain | Apr 15, 2021 |
| CFRA | Buy | Buy | Maintain | Apr 24, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 31, 2020 |
| PiperJaffray | Overweight | Overweight | Maintain | Dec 9, 2019 |
| Bank of America | Buy | Buy | Maintain | Oct 24, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 23, 2019 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 24, 2019 |
| Guggenheim | Neutral | Buy | Downgrade | Oct 2, 2018 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Feb 2, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Feb 2, 2017 |
| Cowen & Co. | Outperform | Outperform | Maintain | Dec 7, 2016 |
| Northland Securities | Outperform | Market Perform | Upgrade | Nov 8, 2016 |
| Northland Capital Markets | Outperform | Market Perform | Upgrade | Nov 8, 2016 |
| Leerink Swann | Outperform | Outperform | Maintain | Apr 4, 2016 |
| Nomura | Buy | Buy | Maintain | Mar 17, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Mar 7, 2016 |
| Sterne Agee | Neutral | Buy | Downgrade | Nov 7, 2014 |
| CRT Capital | Buy | Buy | Maintain | Oct 23, 2014 |
| Wunderlich Securities | Hold | Hold | Maintain | Apr 24, 2013 |
| Wunderlich | Hold | Hold | Maintain | Apr 24, 2013 |
| Lazard | Neutral | Buy | Downgrade | Apr 24, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $85.76. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $110 | $83.04 | +28.3% | Jul 28, 2026 |
| Piper Sandler | Analyst unavailable | $101 | $83.82 | +17.8% | Jul 24, 2026 |
| Leerink Partners | Mike Kratky | $101 | $83.82 | +17.8% | Jul 24, 2026 |
| Truist Financial | Richard Newitter | $95 | $86.78 | +10.8% | Jul 16, 2026 |
| RBC Capital | Analyst unavailable | $110 | $92.02 | +28.3% | Jul 13, 2026 |
| Evercore ISI | Analyst unavailable | $100 | $93.12 | +16.6% | Jul 6, 2026 |
| BTIG | Marie Thibault | $110 | $91.18 | +28.3% | Jun 30, 2026 |
| Barclays | Analyst unavailable | $110 | $84.15 | +28.3% | Apr 27, 2026 |
| Truist Financial | Analyst unavailable | $90 | $83.15 | +4.9% | Apr 24, 2026 |
| Evercore ISI | Vijay Kumar | $93 | $83.12 | +8.4% | Apr 24, 2026 |
| BTIG | Analyst unavailable | $100 | $79.72 | +16.6% | Apr 24, 2026 |
| Canaccord Genuity | William Plovanic | $85 | $79.72 | -0.9% | Apr 24, 2026 |
| Mizuho Securities | Analyst unavailable | $95 | $77.28 | +10.8% | Apr 13, 2026 |
| Truist Financial | Richard Newitter | $89 | $76.85 | +3.8% | Feb 11, 2026 |
| Goldman Sachs | David Roman | $95 | $77.05 | +10.8% | Feb 11, 2026 |
| Piper Sandler | Analyst unavailable | $100 | $77.05 | +16.6% | Feb 11, 2026 |
| UBS | Danielle Antalffy | $94 | $81.62 | +9.6% | Feb 4, 2026 |
| Stifel Nicolaus | Analyst unavailable | $110 | $84.35 | +28.3% | Jan 20, 2026 |
| Piper Sandler | Analyst unavailable | $98 | $84.35 | +14.3% | Jan 20, 2026 |
| UBS | Danielle Antalffy | $95 | $83.58 | +10.8% | Jan 12, 2026 |
| Robert W. Baird | Analyst unavailable | $90 | $83.69 | +4.9% | Jan 12, 2026 |
| Barclays | Analyst unavailable | $104 | $85.13 | +21.3% | Jan 12, 2026 |
| Goldman Sachs | David Roman | $108 | $84.58 | +25.9% | Jan 9, 2026 |
| Stifel Nicolaus | Rick Wise | $105 | $85.85 | +22.4% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $94 | $84.34 | +9.6% | Jan 5, 2026 |
| Wells Fargo | Analyst unavailable | $100 | $84.84 | +16.6% | Dec 18, 2025 |
| Canaccord Genuity | William Plovanic | $87 | $85.32 | +1.4% | Dec 17, 2025 |
| Robert W. Baird | David Rescott | $87 | $83.38 | +1.4% | Dec 16, 2025 |
| Barclays | Analyst unavailable | $103 | $86.19 | +20.1% | Dec 8, 2025 |
| UBS | Analyst unavailable | $92 | $86.58 | +7.3% | Dec 5, 2025 |
| RBC Capital | Shagun Singh | $100 | $87.34 | +16.6% | Dec 5, 2025 |
| Robert W. Baird | David Rescott | $88 | $85.78 | +2.6% | Dec 5, 2025 |
| Canaccord Genuity | William Plovanic | $89 | $85.78 | +3.8% | Dec 5, 2025 |
| Wells Fargo | Larry Biegelsen | $96 | $85.78 | +11.9% | Dec 5, 2025 |
| Stifel Nicolaus | Rick Wise | $100 | $85.78 | +16.6% | Dec 5, 2025 |
| Truist Financial | Richard Newitter | $92 | $85.78 | +7.3% | Dec 5, 2025 |
| BTIG | Marie Thibault | $103 | $85.78 | +20.1% | Dec 4, 2025 |
| Bernstein | Lee Hambright | $90 | $82.45 | +4.9% | Nov 3, 2025 |
| UBS | Analyst unavailable | $90 | $82.45 | +4.9% | Nov 3, 2025 |
| Canaccord Genuity | William Plovanic | $84 | $82.45 | -2.1% | Nov 3, 2025 |
| Raymond James | Jayson Bedford | $96 | $82.45 | +11.9% | Nov 3, 2025 |
| National Bank | Analyst unavailable | $92 | $82.46 | +7.3% | Oct 31, 2025 |
| Goldman Sachs | Analyst unavailable | $104 | $84.48 | +21.3% | Oct 31, 2025 |
| RBC Capital | Analyst unavailable | $95 | $83.29 | +10.8% | Oct 31, 2025 |
| Robert W. Baird | David Rescott | $83 | $83.29 | -3.2% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $99 | $83.48 | +15.4% | Oct 31, 2025 |
| Jefferies | Matthew Taylor | $98 | $82.19 | +14.3% | Oct 29, 2025 |
| Truist Financial | Analyst unavailable | $87 | $83.08 | +1.4% | Oct 28, 2025 |
| Truist Financial | Analyst unavailable | $82 | $80.82 | -4.4% | Oct 27, 2025 |
| Evercore ISI | Analyst unavailable | $88 | $76.56 | +2.6% | Oct 7, 2025 |
| Stifel Nicolaus | Rick Wise | $85 | $74.41 | -0.9% | Sep 22, 2025 |
| Canaccord Genuity | William Plovanic | $75 | $76.04 | -12.5% | Apr 25, 2025 |
| Stifel Nicolaus | Rick Wise | $90 | $71.13 | +4.9% | Jan 29, 2025 |
| Bernstein | Lee Hambright | $74 | $74.15 | -13.7% | Jan 8, 2025 |
| Bernstein | Lee Hambright | $72 | $72.62 | -16.0% | Dec 5, 2024 |
| Truist Financial | Richard Newitter | $78 | $72.64 | -9.0% | Dec 5, 2024 |
| Canaccord Genuity | William Plovanic | $68 | $73.26 | -20.7% | Dec 5, 2024 |
| Goldman Sachs | David Roman | $80 | $68.63 | -6.7% | Oct 30, 2024 |
| Bank of America Securities | Travis Steed | $75 | $68.63 | -12.5% | Oct 30, 2024 |
| Citigroup | Joanne Wuensch | $81 | $69.05 | -5.6% | Oct 28, 2024 |
| Robert W. Baird | David Rescott | $73 | $69.63 | -14.9% | Oct 15, 2024 |
| Morgan Stanley | Patrick Wood | $70 | $68.26 | -18.4% | Oct 11, 2024 |
| Canaccord Genuity | William Plovanic | $66 | $65.49 | -23.0% | Oct 7, 2024 |
| Jefferies | Matthew Taylor | $70 | $67.23 | -18.4% | Sep 18, 2024 |
| Truist Financial | Richard Newitter | $71 | $68.13 | -17.2% | Sep 13, 2024 |
| Barclays | Matt Miksic | $80 | $66.81 | -6.7% | Sep 9, 2024 |
| Wells Fargo | Larry Biegelsen | $80 | $66.81 | -6.7% | Sep 9, 2024 |
| Daiwa | Narumi Nakagiri | $72 | $63.64 | -16.0% | Jul 31, 2024 |
| Citigroup | Joanna Wuensch | $83 | $63.74 | -3.2% | Jul 30, 2024 |
| Deutsche Bank | Pito Chickering | $85 | $60.58 | -0.9% | Jul 25, 2024 |
| Stifel Nicolaus | Rick Wise | $70 | $86.95 | -18.4% | Jul 25, 2024 |
| Piper Sandler | Adam Maeder | $73 | $86.95 | -14.9% | Jul 25, 2024 |
| Truist Financial | Richard Newitter | $110 | $89.5 | +28.3% | Jul 16, 2024 |
| Goldman Sachs | David Roman | $107 | $87.03 | +24.8% | May 30, 2024 |
| Deutsche Bank | Pito Chickering | $103 | $84.7 | +20.1% | May 14, 2024 |
| RBC Capital | Shagun Singh | $101 | $90.28 | +17.8% | Apr 15, 2024 |
| Mizuho Securities | Anthony Petrone | $105 | $91.51 | +22.4% | Apr 11, 2024 |
| Oppenheimer | Suraj Kalia | $100 | $92.85 | +16.6% | Mar 18, 2024 |
| Canaccord Genuity | Analyst unavailable | $76 | $78.21 | -11.4% | Feb 1, 2023 |
| Truist Financial | Analyst unavailable | $86 | $76.7 | +0.3% | Feb 1, 2023 |
| Morgan Stanley | Analyst unavailable | $95 | $76.32 | +10.8% | Jan 6, 2023 |
| Raymond James | Analyst unavailable | $83 | $75.32 | -3.2% | Dec 13, 2022 |
| Citigroup | Analyst unavailable | $92 | $75.26 | +7.3% | Dec 12, 2022 |
| Stifel Nicolaus | Rick Wise | $75 | $73.85 | -12.5% | Dec 5, 2022 |
| RBC Capital | Analyst unavailable | $105 | $75.98 | +22.4% | Nov 28, 2022 |
| RBC Capital | Shagun Singh Chadha | $118 | $70.87 | +37.6% | Oct 28, 2022 |
| Truist Financial | Richard Newitter | $120 | $100.54 | +39.9% | Jul 30, 2022 |
| Canaccord Genuity | Analyst unavailable | $137 | $111.59 | +59.7% | Apr 27, 2022 |
| Raymond James | Analyst unavailable | $124 | $111.86 | +44.6% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $135 | $116.27 | +57.4% | Apr 27, 2022 |
| Leerink Partners | Analyst unavailable | $138 | $116.27 | +60.9% | Apr 27, 2022 |
| Evercore ISI | Vijay Kumar | $126 | $120.36 | +46.9% | Apr 6, 2022 |
| Bank of America Securities | Travis Steed | $130 | $111.98 | +51.6% | Mar 3, 2022 |
| Leerink Partners | Danielle Antalffy | $130 | $101.96 | +51.6% | Jan 27, 2022 |
| Stifel Nicolaus | Rick Wise | $120 | $101.96 | +39.9% | Jan 27, 2022 |
| Morgan Stanley | Cecilia Furlong | $136 | $101.96 | +58.6% | Jan 27, 2022 |
| Deutsche Bank | Pito Chickering | $113 | $108.63 | +31.8% | Jan 26, 2022 |
| Credit Suisse | Matt Miksic | $140 | $122.3 | +63.2% | Jan 7, 2022 |
| J.P. Morgan | Robbie Marcus | $140 | $122.12 | +63.2% | Dec 17, 2021 |
| Oppenheimer | Suraj Kalia | $135 | $120.34 | +57.4% | Dec 9, 2021 |
| Wells Fargo | Larry Biegelsen | $133 | $120.34 | +55.1% | Dec 9, 2021 |
| Cowen & Co. | Josh Jennings | $140 | $120.34 | +63.2% | Dec 9, 2021 |
| Jefferies | Anthony Petrone | $135 | $119.54 | +57.4% | Nov 8, 2021 |
Track every rating change on EW the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
-1.4%
Event window
SPY move
+0.1%
Same window
Abnormal move
-1.5%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
+3.8%
Up to 20 sessions
EWSPY benchmark
Follow EW with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Full-year sales guidance raised from 8-10% to 10-11% growth. TAVR guidance increased to 8-9% and TMTT revenue guidance set at $760-780 million. A competitor exit contributed to TAVR market share gains. First patients treated with next-generation SAPIEN X4S platform. CE Mark awarded for SAPIEN M3 RESILIA with expanded MAC indication. Q2 sales growth accelerated to 12.5% YoY from 11.6% YoY in Q4 2025.
Guidance delta
Management raised full-year 2026 sales growth guidance from 8-10% to 10-11%. TAVR growth guidance was increased to 8-9%, and TMTT revenue guidance was introduced at $760-780 million. The earnings outlook was reaffirmed despite tax and FX headwinds.
Key takeaways
- Q2 sales grew 12.5% YoY to $1.74 billion, with EPS of $0.78 beating estimates by 5.0%.
- Full-year sales guidance raised to 10-11% growth; TAVR guidance to 8-9% and TMTT revenue guidance to $760-780 million.
- Strong adoption of TAVR (SAPIEN) and TMTT platforms (PASCAL, EVOQUE, SAPIEN M3) across all regions.
- Upcoming clinical data (PROGRESS, ALLIANCE) and regulatory milestones (CMS NCD, asymptomatic indication, PASCAL tricuspid approval) expected to drive future growth.
- Balance sheet remains robust with $2.9 billion cash and $1.5 billion remaining share-repurchase authorization.
Management priorities
- Commercial launch of next-generation SAPIEN X4S platform
- U.S. launch of PASCAL for tricuspid patients planned for Q4 2026
- Rollout of surgical left atrial appendage device ECLIPTIS in the U.S.
- Presentation of PROGRESS trial results at TCT later in the year
- Continued R&D investment and completion of the ALLIANCE trial for next-gen SAPIEN
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-07-24T16:08:48.839161+00:00
- FN2 earnings calendar · 2026-07-29T01:23:15.868211+00:00
- Polygon adjusted daily market bars · 2026-07-30T00:22:14.238661+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T00:22:14.235988+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.